These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 19684544)

  • 1. Should we be using activated protein C to treat severe sepsis?
    Eve RL; Duffy MR
    Br J Hosp Med (Lond); 2009 Aug; 70(8):484. PubMed ID: 19684544
    [No Abstract]   [Full Text] [Related]  

  • 2. [Recombinant activated protein C: from evidence to clinical practice. Clinical practice guidelines for the use of activated proteins C in the treatment of severe sepsis].
    Heslet L; Nielsen JD; Schierbeck J; Andersen JS
    Ugeskr Laeger; 2004 Mar; 166(11):997-1002. PubMed ID: 15049234
    [No Abstract]   [Full Text] [Related]  

  • 3. Risks and benefits of activated protein C treatment for severe sepsis.
    Warren HS; Suffredini AF; Eichacker PQ; Munford RS
    N Engl J Med; 2002 Sep; 347(13):1027-30. PubMed ID: 12324562
    [No Abstract]   [Full Text] [Related]  

  • 4. [Questionable efficacy and safety of activated drotrecogin alpha (activated protein C) in the treatment of severe sepsis].
    Girbes AR; Polderman KH; Beishuizen A; van Zanten AR; Schultz MJ
    Ned Tijdschr Geneeskd; 2006 Jun; 150(22):1265-6; author reply 1266. PubMed ID: 16796179
    [No Abstract]   [Full Text] [Related]  

  • 5. Reassessing recombinant human activated protein C for sepsis: time for a new randomized controlled trial.
    Eichacker PQ; Danner RL; Suffredini AF; Cui X; Natanson C
    Crit Care Med; 2005 Oct; 33(10):2426-8. PubMed ID: 16215410
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacology, clinical efficacy, and safety of drotrecogin alfa (activated).
    Rudis MI; Fish DN
    Pharmacotherapy; 2002 Dec; 22(12 Pt 2):182S-195S. PubMed ID: 12492225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the use of activated protein C in the treatment of severe sepsis.
    Siegel JP
    N Engl J Med; 2002 Sep; 347(13):1030-4. PubMed ID: 12324563
    [No Abstract]   [Full Text] [Related]  

  • 8. [Sepsis therapy -- how effective are the therapy strategies?].
    Brunkhorst F; Reinhart K
    Chirurg; 2008 Sep; 79(9):877-8. PubMed ID: 18942197
    [No Abstract]   [Full Text] [Related]  

  • 9. Drotrecogin alfa (activated) approved for treatment of severe sepsis.
    Poe K
    J Am Pharm Assoc (Wash); 2002; 42(3):520-2. PubMed ID: 12030642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant human activated protein C in sepsis: inconsistent trial results, an unclear mechanism of action, and safety concerns resulted in labeling restrictions and the need for phase IV trials.
    Eichacker PQ; Natanson C
    Crit Care Med; 2003 Jan; 31(1 Suppl):S94-6. PubMed ID: 12544982
    [No Abstract]   [Full Text] [Related]  

  • 11. Role of activated protein C in the pathophysiology of severe sepsis.
    Dettenmeier P; Swindell B; Stroud M; Arkins N; Howard A
    Am J Crit Care; 2003 Nov; 12(6):518-24; quiz 525-6. PubMed ID: 14619357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What is the role of recombinant activated protein C in the management of sepsis?
    Alvarado J; Castro R
    Medwave; 2016 Dec; 16(Suppl5):e6801. PubMed ID: 28032853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conclusions: drotrecogin alfa (activated)--from bench to practical use at the bedside.
    Maki DG
    Am J Surg; 2002 Dec; 184(6A Suppl):S47-50. PubMed ID: 12521617
    [No Abstract]   [Full Text] [Related]  

  • 14. Drotrecogin alfa on trial.
    Tillotson GS
    Lancet Infect Dis; 2009 Jan; 9(1):2-3. PubMed ID: 19095188
    [No Abstract]   [Full Text] [Related]  

  • 15. Drotrecogin alfa (activated) administration: too many subgroups.
    Carlet J
    Crit Care Med; 2003 Oct; 31(10):2564; author reply 2564-5. PubMed ID: 14530774
    [No Abstract]   [Full Text] [Related]  

  • 16. Recombinant human activated protein C sentenced to the death of a thousand cuts?
    O'Brien JM
    Crit Care Med; 2007 Jun; 35(6):1609-10. PubMed ID: 17522532
    [No Abstract]   [Full Text] [Related]  

  • 17. [Surgical patients with severe sepsis: first results of the PROWESS study. Demographic data].
    Montravers P; Blaise M
    Ann Fr Anesth Reanim; 2003 Dec; 22 Spec No 1():38-9. PubMed ID: 15359941
    [No Abstract]   [Full Text] [Related]  

  • 18. Activated protein C: do more survive?
    Macias WL
    Intensive Care Med; 2006 Apr; 32(4):605-7; author reply 610-2. PubMed ID: 16508756
    [No Abstract]   [Full Text] [Related]  

  • 19. Activated protein C: do more survive?
    Ridley S
    Intensive Care Med; 2006 Apr; 32(4):608; author reply 610-2. PubMed ID: 16508755
    [No Abstract]   [Full Text] [Related]  

  • 20. [Xigris--activated protein C].
    Tønnesen EK
    Ugeskr Laeger; 2004 Mar; 166(11):1002-4. PubMed ID: 15049235
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.